Venturepharm Laboratories Limited ( China (Mainland))

Venturepharm Laboratories Limited, a member of Venturepharm Holdings, is a listed company on the Hong Kong Stock Market (8225). It is the largest global provider of pharmaceutical development service in China. Venturepharm provides full service of drug discovery and development that take new drugs from "Idea to patients". These include Active Pharmaceutical Ingredient such as Riluzole with cas registry number of 1744-22-5, Piribedil with cas registry number of 3605-01-4, Oxiranemethanol acetate with cas registry number of 6387-89-9, formulation development, clinical trial, product registration, marketing & sales to pharmaceutical distributors and patients in China and overseas.

Venturepharm has experienced dramatic success since its inception in 1999. Powered with 7 of VSmart® technology platforms, it has over 400 non-patent infringed products approved. In addition, 6 of NCEs (new chemical entities) are at preclinical stage. These products encompass over 13 major therapeutic areas. In 2004, Venturepharm was valued by FORTUNE magazine as one of the five most promising companies in China. Since 2000, Venturepharm has achieved revenue CAGR of 133% and EPS CAGR of 383% annually.

Today, apart from the founding members, its investors include C Tech Fund, the Government of Singapore Investment Corporation, Kerry Group, K. Wah Group, SUNeVision, JAFCO and public investors. Currently Venturepharm has more than two thousand employees.